Pulse Biosciences Free Cash Flow (FCF) History (PLSE)

Pulse Biosciences reported −$54.4M in free cash flow for fiscal 2025, a decrease of $18.0M from the previous fiscal year, with a free cash flow margin of −15553.43%.

View full Pulse Biosciences company overview

Pulse Biosciences free cash flow by year

Pulse Biosciences annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$54.4M−$18.0M−15553.43%
20242024-12-31−$36.5M−$3.3M
20232023-12-31−$33.2M$14.3M
20222022-12-31−$47.4M$7.1M−6773.43%
20212021-12-31−$54.5M−$18.7M−3845.84%
20202020-12-31−$35.8M−$1.0M
20192019-12-31−$34.8M−$10.6M
20182018-12-31−$24.2M−$10.5M
20172017-12-31−$13.6M−$5.5M
20162016-12-31−$8.1M−$4.7M
20152015-12-31−$3.4M

Pulse Biosciences free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$35.8M to −$54.4M, a net decrease of $18.6M. Pulse Biosciences's latest reported quarter, Q2 2026, generated −$18.8M in free cash flow, a decrease of $5.9M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Pulse Biosciences filings at SEC.gov ↗